HOW NOVAVAX, INC. (NASDAQ:NVAX) IS KEEPING THE PRESSURE ON SHORTS
Oct 1, 2018 | Business
Shares of Novavax, Inc. (NASDAQ:NVAX) continue to act well in a rising market on rising volume. Helping to push the action, most recently, the company announced the initiation of a Phase 2 dose and formulation confirmation clinical trial in older adults of NanoFlu, its nanoparticle seasonal influenza vaccine candidate.
“Initiating this Phase 2 clinical trial of NanoFlu is an important milestone for Novavax,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “With top-line results expected in the first quarter of 2019, we plan to discuss these data with the FDA at an ‘End of Phase 2’ meeting and to agree on the appropriate Phase 3 clinical trial design to support licensure via accelerated approval. We continue to believe NanoFlu is a differentiated flu vaccine capable of better addressing a global public health problem, and can thereby capture a significant share of the multi-billion-dollar seasonal influenza vaccine market.” >>>>
